Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.

Li, Xinli.
Liu, Chun.
Ip, Blanche C.
Hu, Kang-Quan.
Smith, Donald E.
Greenberg, Andrew S.
Wang, Xiang-Dong.
2015

Background: Tumor progression locus 2 (TPL2), a serine-threonine kinase, functions as a critical regulator of inflammatory pathways and mediates oncogenic events. The potential role of Tpl2 in nonalcoholic fatty liver disease (NAFLD) associated hepatocellular carcinoma (HCC) development remains unknown.

Permanent URL
http://hdl.handle.net/10427/010225
Original publication
Li, Xinli, Chun Liu, Blanche C. Ip, Kang-Quan Hu, Donald E. Smith, Andrew S. Greenberg, and Xiang-Dong Wang. "Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice." Journal of Experimental & Clinical Cancer Research 34, no. 1 (12, 2015): 1-8.
ID: tufts:17545
To Cite: DCA Citation Guide
Usage: Detailed Rights